Molecular Biology Reports

, Volume 37, Issue 6, pp 2909–2914 | Cite as

Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2

  • Seyyed Mahmoud Ebrahimi
  • Majid Tebianian
  • Khosrow Aghaiypour
  • Hassan Nili
  • Ali Mirjalili


The conserved M2 protein of influenza A virus is considered as a promising candidate target for a broad-spectrum, recombinant influenza A vaccine. In the present study, the open reading frame (ORF) of avian influenza A/chicken/Iran/101/1998 (H9N2) M2 gene was amplified then cloned in pAED4, prokaryotic expression vector. M2 protein was produced through the expression of this recombinant expression vector (pAED4-M2) in E. coli BL21 (DE3) strain. The expressed M2 protein was analyzed on SDS-PAGE. Western blot assay was used to examine the immunoreaction of the expressed protein using commercial polyclonal anti-M2 antibody. The antigenicity and biological activity of the recombinant protein was also qualitatively detected on infected MDCK cells surface by immunofluorescence assay using rabbit’s immunized antiserum. So, according to the sequence alignment based on the mentioned isolate and the result of immunoassay reaction, it seems recombinant vaccine based on A/chicken/Iran/101/1998(H9N2) M2 protein isolate might cover majority of influenza A virus strains specially H5 and H9 circulating in Iran and neighbor regions significantly.


M2 protein pAED4 SDS-PAGE Expression Avian influenza 



This project was financially supported by a grant of the Razi Vaccine and Serum Research Institute (RVSRI). The authors wish to thank Dr. Paykari, Dr. Lotfi, Dr. Khaki, Dr. Mirafzali, and Dr. Momays faculty members of Razi Vaccine and Serum Research Institute for their helpful contribution to this project.


  1. 1.
    Epstein SL, Stack A, Misplon JA, Lo CY, Mostowski H, Bennink J, Subbarao K (2000) Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes: either CD4+ or CD8+ T cells can promote survival and recovery after challenge. Int Immunol 12:91–101CrossRefPubMedGoogle Scholar
  2. 2.
    Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749CrossRefPubMedGoogle Scholar
  3. 3.
    Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8:796–801PubMedGoogle Scholar
  4. 4.
    Zebedee SL, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virion. J Virol 62:2762–2772PubMedGoogle Scholar
  5. 5.
    Ebrahimi SM, Aghaiypour K, Nili H (2008) Sequence analysis of M2 gene of avian influenza virus strain (A/chicken/Iran/101/98 (H9N2)) as an oil vaccine seed. Iran J Biotechnol 6(4):235–238Google Scholar
  6. 6.
    Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993–3003CrossRefPubMedGoogle Scholar
  7. 7.
    Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus- expressed M2 protein. Vaccine 13:1399–1402CrossRefPubMedGoogle Scholar
  8. 8.
    Frace AM, Klimov AI, Rowe T, Black RA, Katz JM (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237–2244CrossRefPubMedGoogle Scholar
  9. 9.
    Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza V vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157–1163CrossRefPubMedGoogle Scholar
  10. 10.
    Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos JL, Gerhard W (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21:2616–2626CrossRefPubMedGoogle Scholar
  11. 11.
    Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K, Ohnari K, Nakajima K, Xin KQ (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19:3681–3691CrossRefPubMedGoogle Scholar
  12. 12.
    Watabe S, Xin K-Q, Ihata A, Liu L-J, Honsho A, Aoki I, Hamajima K, Wahren B, Okuda K (2001) Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434–4444CrossRefPubMedGoogle Scholar
  13. 13.
    Martin K, Helenius A (1991) Transport of incoming influenza virus nucleocapsids into the nucleus. J Virol 65:232–244PubMedGoogle Scholar
  14. 14.
    De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337(1):149–161CrossRefPubMedGoogle Scholar
  15. 15.
    Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED (1987) Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 139(6):2010–2014PubMedGoogle Scholar
  16. 16.
    Johansson BE, Kilbourne ED (1993) Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67(10):5721–5723PubMedGoogle Scholar
  17. 17.
    Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos LJ, Gerhard W (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21(19–20):2616–2626CrossRefPubMedGoogle Scholar
  18. 18.
    Andrea J, Nicole S, Tazio S, Martin FB (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172:5598–5605Google Scholar
  19. 19.
    Lamb RA, Lai CJ, Choppin PW (1981) Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: Colinear and interrupted mRNAs code for overlapping proteins. Proc Natl Acad Sci 78(7):4170–4174CrossRefPubMedGoogle Scholar
  20. 20.
    Zebedee SL, Richardson CD, Lamb RA (1985) Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J Virol 56(2):502–511PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Seyyed Mahmoud Ebrahimi
    • 1
  • Majid Tebianian
    • 1
  • Khosrow Aghaiypour
    • 1
  • Hassan Nili
    • 2
  • Ali Mirjalili
    • 1
  1. 1.Department of BiotechnologyRazi Vaccine and Serum Research InstituteKarajIran
  2. 2.Department of Avian Medicine, School of Veterinary MedicineShiraz UniversityShirazIran

Personalised recommendations